Maintaining fluoroquinolone class efficacy: review of influencing factors. - Wikidata - wikimedia - TriplyDB

Maintaining fluoroquinolone class efficacy: review of influencing factors.

Maintaining fluoroquinolone class efficacy: review of influencing factors.

http://www.wikidata.org/entity/Q30310427

about

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis Bacteria tracking by in vivo magnetic resonance imaging.Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study.Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia.The fluoroquinolones: how long will their utility last?Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Resistance to antimicrobial agents: an update.Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients.Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.Fluoroquinolone prescriptions in a teaching hospital: a prospective audit.Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Fluoroquinolones in the management of community-acquired pneumonia.Emerging drugs for pneumococcal pneumonia.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Elderly patients with community-acquired pneumonia: optimal treatment strategies.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Levofloxacin for the treatment of respiratory tract infections.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.Gram-negative and Gram-positive bacterial infections give rise to a different metabolic response in a mouse model Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care-Associated Pneumonia.Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.Antibiotic rotation and development of gram-negative antibiotic resistance.Quinolone safety and efficacy more important than potency.Factors influencing fluoroquinolone resistance.Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.Antiproliferative and cytotoxic properties of moxifloxacin on rat retinal ganglion cells.Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.Monitoring of antibiotic resistance in bacterial isolates from bacteremic patients.Prevalence of tetM, tetQ, nim and bla(TEM) genes in the oral cavities of Greek subjects: a pilot study.Quinolone Safety and Efficacy.Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

P2860

Q22241905-8C23ACC3-C914-412B-BC9C-38E5B0BDCBAB Q24803536-6D896D1F-1DDB-47AC-8750-6512369E9781 Q30540773-7A6CFB9F-1D4B-482E-AC63-0FFD025C79B9 Q30939930-7514F114-B0A0-4DE1-A128-68983AA45FA8 Q34394167-21D2EF15-6B47-4EDC-816A-54C9E33C1C84 Q35024966-1CD41E2D-1995-45C9-B6EB-DA74A5FCB477 Q35164756-3A6AA07D-B923-49CF-B8F5-6CFF0880E7F4 Q35241405-84D1267B-ACB1-4D30-843F-DE2555952A77 Q35733987-1710CBEE-77EF-4F17-A95E-5C4F615E172E Q35917226-4B61C3D3-9F97-447C-BFBB-589A5686283B Q35917230-894A46A8-3C5F-4C8C-853C-91F93D005D1F Q35964560-830AB469-F530-450E-A73D-0DF77680A84D Q35976850-E20749C4-9E0E-4970-ADF3-88DAD78A5C75 Q36477037-0BAEC660-EA0A-4265-9465-132EC16ABBC0 Q36765740-0299BA67-2CAA-462D-8DB1-F753BEAFB08C Q36939682-F683735C-0477-4D3D-BE49-39D173F612D9 Q37071001-672660F3-A163-4DCC-B776-AB0E3C935B6C Q37733449-0806A3CE-A5B0-47D8-B4C0-633856DC950A Q37747693-33F52799-6174-4718-8143-FD1824C83EE9 Q37864327-BB8AC7A9-FDAD-4D73-B8FE-DF0E3845CC2E Q37868241-B3430E3C-2DFD-4F44-940F-1B3A4184D71C Q37896600-486D6BAC-211E-4DCE-997E-D18A685D0B14 Q37982661-A78D762E-51B3-4F28-9B99-04C44C55DB4C Q38010784-503B44BB-7E88-499E-900B-9B2727F5F696 Q38056764-CFC800C8-938C-44EA-96BC-F14E40C63676 Q39631903-B23011F5-AB68-4EEE-ADD3-7D130E175E90 Q40090523-77AC74DA-657E-40FD-BD97-BB9B7D3EBE8B Q40448254-6514D5BD-D050-4BE4-9BD3-8F33C4F38C8F Q42164346-5779A286-476C-4F26-A8F4-C1359669C6FF Q42552109-A3BB994B-77EC-43F0-B30E-38B787C552E0 Q42590584-534609D0-0CDE-4903-A9D9-E18F5927A76E Q43067626-B5158EEA-4CE3-42EE-B922-C2C1208D347E Q43181838-4FB83D28-6C8E-4618-9A54-13BF2637BDFC Q44673050-AE9E9D9A-59B2-444B-92EC-E6F0671A2DB6 Q44904811-349D07F8-454D-40A1-A71E-AD2634E51A19 Q45031132-913358A4-E67E-422D-BC8A-C4BE4EBF1B4D Q45963216-CE443DFB-8F22-46FE-9418-AB8DCF95188A Q45972915-DAD7DEE6-1795-45B9-8C88-D312D5CF2B90 Q46762887-ABF213C6-BCA1-4C72-82BA-70D2FD341C12 Q47101582-C5E4A20C-31CA-4770-99E7-B0E98E349CB0

P2860

Maintaining fluoroquinolone class efficacy: review of influencing factors.

http://www.wikidata.org/entity/Q30310427

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@ast

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@en

type

label

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@ast

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@en

prefLabel

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@ast

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@en

P1433

Q30310427-D7EF6B99-F4C2-4D65-8097-0CC6D6C10DDE

P1476

Q30310427-BCDEFB99-9749-4EDA-B0AF-E510505BB820

P2093

Q30310427-7B72B23F-02F8-4C1C-BF3D-9BE1F68209FD

P2860

Q30310427-0115F4FA-4E5A-4E93-89EB-B82CBB4B3026

Q30310427-06948310-63A3-4142-875B-767236BDEED2

Q30310427-0A05E466-05FE-4EA1-8668-39A84957E3B1

Q30310427-0B3B2556-6D03-47B1-AAD1-DF75B7F16C3C

Q30310427-0B4B2668-8391-4739-9699-148808C5241A

Q30310427-11300B50-FD2F-421A-9184-05ED18D46A33

Q30310427-2DF1DED3-6691-4827-9E88-AC48FB8C4924

Q30310427-2F15E6E1-C27D-42CC-B785-467331F968E7

Q30310427-33DCC181-BB4C-479B-9623-C7E45E18E30F

Q30310427-344682DE-291F-4E13-95C3-F3ED17186394

P304

Q30310427-8020D244-C020-4425-8330-350372A46021

P31

Q30310427-22EB309F-5941-4A96-AE67-7F39917091B5

Q30310427-EE943C20-DA66-4F48-B24D-670C1B4D3000

P356

Q30310427-D3ACF4F2-4694-4664-BB2B-292A024DBDAA

P433

Q30310427-16FE61A8-FFEB-46AB-8348-8EB64D071E2F

P478

Q30310427-33DB5782-E31C-4246-ABD2-0123B7A466FA

P577

Q30310427-22A9AC3D-6ABB-4ACC-82FE-87F8D820E224

P5875

Q30310427-08181E7F-E0BC-4805-A48E-6E29E572A402

P698

Q30310427-241411F3-AC05-48BC-81F1-557BF61FB601

P921

Q30310427-7CEFA6C3-D22A-4951-9D2B-DA9156229F32

Q30310427-7D259F62-F733-4DBE-AC58-7911185DCBA2

P932

Q30310427-DBFF7234-AA96-4405-ABC7-A97AA9BC252E

P356

P1433

Emerging Infectious Diseases

P1476

Maintaining fluoroquinolone class efficacy: review of influencing factors.

@en

P2093

W Michael Scheld

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

A critical review of the fluoroquinolones: focus on respiratory infections

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID0901.020277

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10946528

http://www.w3.org/2001/XMLSchema#string

P698

12533274

http://www.w3.org/2001/XMLSchema#string

P921

physiological phenomena

bacterial infectious disease

P932

2873754

http://www.w3.org/2001/XMLSchema#string